InvestorsHub Logo
Followers 20
Posts 5388
Boards Moderated 0
Alias Born 01/04/2012

Re: silvr_surfr post# 14515

Tuesday, 10/17/2023 2:31:40 PM

Tuesday, October 17, 2023 2:31:40 PM

Post# of 14973
Silvr, I would not be surprised if ANIP/Novitium got the rights to Nuray Chemicals IP related to Tafamidis, and have entered into a collaborative agreement with Pfizer to develop a replacement for a new and improved version of their Vyndamax® (Tafamidis), and Vyndaqel® (tafamidis meglumine) which starts to lose some patents and exclusivity December 2023 through 2024. This will allow Pfizer to switch their patients to the new drug which patent coverage extends to 2041.

Nuray Patent

Samy is the lead inventor for the patent.

Vyndaquel IP expiration

Vyndamax IP expration

FYI, Vyndaquel and Vyndamax accounted for $782 million in revenue for Pfizer in Q2.

JMHO
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ANIP News